Related references
Note: Only part of the references are listed.TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G. R. Oxnard et al.
ANNALS OF ONCOLOGY (2020)
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Adam J Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
Han Na Kang et al.
BMC CANCER (2020)
Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma
David J. H. Shih et al.
NATURE GENETICS (2020)
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer
Filippo de Marinis et al.
FUTURE ONCOLOGY (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor
Xile Liu et al.
CANCER RESEARCH (2019)
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Zheng-Hai Tang et al.
CANCER LETTERS (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination
M. Steklov et al.
SCIENCE (2018)
LZTR1 is a regulator of RAS ubiquitination and signaling
Johannes W. Bigenzahn et al.
SCIENCE (2018)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas
Lauren L. Ritterhouse et al.
MODERN PATHOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Puyu Shi et al.
CANCER LETTERS (2016)
Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity
Giuseppe Roscilli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Metastasis as an evolutionary process
Samra Turajlic et al.
SCIENCE (2016)
CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing
Eric Talevich et al.
PLOS COMPUTATIONAL BIOLOGY (2016)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Modification of Enhancer Chromatin: What, How, and Why?
Eliezer Calo et al.
MOLECULAR CELL (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice through activation of Wnt and ERK1/2 MAPK pathways
C. H. Wilson et al.
ONCOGENE (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
EGFR tyrosine kinase inhibitors in lung cancer: An evolving story
Lecia V. Sequist et al.
ANNUAL REVIEW OF MEDICINE (2008)
Share Paper
